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CHANGES IN COMPLEMENTARITY-DETERMINING REGIONS 
SIGNIFICANTLY ALTER IGG BINDING TO THE NEONATAL FC RECEPTOR 
 
 
NICOLE PICHÉ-NICHOLAS   
 
 
ABSTRACT 
A large body of data exists demonstrating the key role of FcRn in extending the 
half-life of therapeutic antibodies by rescuing them from lysosomal degradation. 
This led to the widely accepted hypothesis that FcRn binding of an IgG via the 
CH2-CH3 interface of Fc correlates with IgG half-life.  Several studies have 
demonstrated that in vivo half-life can be modified by changing the binding 
affinity of IgG to FcRn. These modifications were generated by mutating the 
coding sequence for the Fc region that resulted in enhanced or reduced FcRn 
binding at endosomal pH without enhancing binding at neutral pH. In contrast to 
this, we have observed that the half-lifes of IgG molecules that had showed no 
target-mediated disposition or off-target binding varies widely, even when they 
share identical Fc domains. This led us to hypothesize that domains of IgG 
molecules other than Fc could contribute to the modulation of FcRn binding and 
affect in vivo half-life. This hypothesis was strengthened by recent publications 
by other groups showing a correlation between antibody charge and the FcRn 
affinity and/or in vivo half-life. 
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In this study we explored the role of IgG domains other than the FcRn binding 
domain in altering the affinity between IgG and FcRn and its relation to the in vivo 
half-life. Here we describe a surface plasmon resonance (SPR) based assay 
developed to examine the steady-state binding affinity (KD) of IgG molecules to 
FcRn.  We systematically dissected the contributions of IgG variable domain 
regions in modulating the affinity between FcRn and IgG. Through analysis of a 
broad collection of therapeutic antibodies containing more than 100 unique IgG 
molecules against more than 25 different therapeutic targets we have 
demonstrated that variable domains and in particular CDRs significantly alter 
binding affinity to FcRn, by 10 to 80-fold, whereas heavy and light chain isotypes 
do not.  Because CDRs modulate the affinity between IgG and FcRn in our in 
vitro studies, it is important to understand the role they play in modulation of IgG 
half-life in vivo as this would have far-reaching implications in the half-life 
optimization efforts of IgG therapeutics. 
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INTRODUCTION 
 
FcRn Overview 
The neonatal Fc Receptor (FcRn), also known as the Brambell receptor, is 
responsible for regulating several immunological functions, including 
transmission of immunity from mother to offspring 1-3, extending serum 
persistence of immunoglobulin G (IgG) 4, immunosurveillance in mucosal linings 
5, and antigen presentation 6.  Brambell studied the transmission of IgG from 
mother to young and in 1964 proposed the presence of a receptor that actively 
transfers IgG from mother’s milk to neonate to confer short-term passive 
immunity 2.  In 1985, the receptor protein was isolated from neonatal rat 7, and in 
1989 the genes coding for the receptor were cloned and predicted to be a 
heterodimer of a major histocompatibility complex (MHC)-class-I-like heavy chain 
(FcRn), and the β2-microglobulin (β2m) light chain that is common to all MHC 
class I molecules 8.  This prediction was confirmed when crystal structures of 
FcRn and FcRn bound to the Fc portion of an IgG molecule were solved 9-12.  
Studies of FcRn-deficient neonatal mice, with gene deletions either in the FcRn 
heavy chain or in β2m, revealed they were unable to absorb IgG molecules from 
maternal milk 13, 14.  As adults, FcRn-deficient mice had lower levels of serum IgG 
and increased IgG catabolism compared to wild-type controls 14-16, suggesting 
that in addition to its role in materno-fetal transport of IgG, FcRn prolongs the 
half-life of IgG in the serum throughout life.  The existence of an IgG salvage 
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pathway is demonstrated by the observation that IgG half-life declines at high 
serum concentrations of IgG thus suggesting that a saturable IgG receptor 
protects IgG from catabolism 2, 17.  The half-life of IgG molecules in FcRn-
deficient mice are reduced from about 6-8 days to about one day, the typical half-
life of serum proteins not filtered by the kidney 14.  This suggests that recycling of 
serum IgG occurs in cells that express FcRn.  Despite its name, FcRn continues 
to be expressed throughout life, contributing to both passive and acquired 
immunity.   
 
Currently, most evidence indicates the vascular endothelium as the main site at 
which FcRn protects IgG molecules from catabolism 18, 19. Endothelial cells 
efficiently internalize serum proteins, and IgG molecule uptake has been shown 
to occur via fluid-phased pinocytosis in human endothelial cultures 18.  FcRn is 
expressed on the vascular endothelium of the large vascular beds of skeletal 
muscle and the skin in mice 19.  FcRn has been shown to recycle and transcytose 
IgG molecules in human endothelial cultures 20.  It is widely proposed that FcRn 
may intercept internalized IgG molecules, shifting IgG away from lysosomal 
degradation, and returning it to the circulation, thereby prolonging the persistence 
of IgG in serum 4.  
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IgG Overview 
Immunoglobulin Gs (IgG molecules) are found in serum or other bodily fluids and 
are used by the immune system to identify and neutralize foreign objects, such 
as bacteria and viruses.  Of the five classes of antibodies (IgA, IgD, IgE, IgM and 
IgG), IgG is the most prevalent class in the serum and non-mucosal tissues and 
the only class of antibody that is actively transferred from mother to young to 
confer short-term passive immunity 1.  To date, three complete structures of 
intact IgG have been solved by X-ray diffraction analysis 21-23.  The structures 
show that IgG consists of three segments, two identical fragments of antigen 
binding arms (Fab arms) connected by hinges to one Fc stem.  IgG consists of 
four polypeptide chains, two identical light chains and two identical heavy chains, 
that can be divided into 12 domains.  Light chains consist of a variable light 
domain (VL) and a constant light domain (CL).  Heavy chains consist of a 
variable heavy domain (VH) and three constant heavy domains (CH1, CH2 and 
CH3).  Fab arms consist of VL, CL, VH and CH1 domains and the Fc consists of 
CH2 and CH3 domains.  The variable domains alone contain the regions of IgG 
that bind antigen, known as the paratope.  Variable domains consist of 
framework regions interspersed with three variable loops of β-strands, known as 
the complementarity-determining.regions (CDRs).  The CDRs are the most 
variable part of the molecule and contribute to the diversity of these molecules, 
which allows IgG molecules to recognize a vast repertoire of antigens.  
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Structurally, CDRs are located at the N-terminal regions of the IgG.  IgG structure 
is pictorially described in Figure 1. 
 
 
Figure 1. Structure and schematic of a human IgG molecule.  The figure on the 
left is a space fill model of the crystal structure of an intact human IgG1 (PDB 
code 1IGY), taken from  Wingren et al., 2001 24.  The figure on the right is a 
schematic of a human IgG with variable domain sequence enlarged to show 
framework (FW) regions and complementarity-determining regions (CDRs). 
The pharmacokinetics of different therapeutic IgG molecules varies greatly.  The 
elimination half-lives of therapeutic IgG molecules in humans range from 1.9-27 
days 25.  Investigations of IgG absorption following intramuscular or 
subcutaneous dosing have reported bioavailabilities ranging from 50-100% 26, 27.   
The rate and extent of IgG distribution are dependent on IgG extravasation within 
tissue, distribution within tissue and elimination from tissue 25.  Distribution of IgG 
FW1    CDR1       FW2       CDR2      FW3        CDR3    FW4
CH2 CH2
CH3 CH3
CL
CH
1 CH1
CL
VL
VH
VH
VL
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within tissue is dependent on convection, IgG binding to cellular antigens, and 
receptor-mediated endocytosis.  The elimination rate of IgG is known to be 
concentration-dependent 28.  Variation in elimination of different IgG molecules 
has been observed because IgG elimination can be tissue specific, vary at sites 
that are not in rapid equilibrium with the blood, and be target-mediated. Other 
than FcRn-dependent recycling, the main determinants of IgG half-life are tissue 
distribution, antigen binding and catabolism.   
 
Functional and Structural Interaction of IgG with FcRn 
The intracellular pathway of FcRn-mediated IgG recycling begins with fluid phase 
pinocytosis of IgG and binding to FcRn in the acidified endosomal compartment.  
At endosomal pH (<6.5), key contact histidine residues on IgG are protonated on 
their imidazole side chains and rapidly associate with FcRn present in the 
endosome 11.  Upon binding to FcRn in the endosome, IgG then enters the 
lysosomal pathway 18.  Vesicles containing FcRn bud off from the endosome and 
travel to the plasma membrane 29, where a rapid kiss-and-run fusion occurs 30.  
When fusion with the plasma membrane occurs, the pH changes to neutral and 
the key contact histidine residues are no longer positively charged causing a 
rapid dissociation of IgG from FcRn and a return of IgG to the circulation.  Thus, 
FcRn interacts with IgG in a pH dependent manner that protects IgG from 
degradation by preventing IgG from entering lysosomes (Figure 2).  
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Figure 2. Proposed role for FcRn in adult endothelial cells.  The neonatal Fc 
receptor for IgG (FcRn) is expressed by endothelial cells and circulating 
monocytes. These cells internalize serum IgG, which binds to FcRn in an acidic 
endosomal compartment. FcRn then recycles IgG back into circulation, thus 
extending its serum half-life. Serum proteins without a recycling receptor are 
destined for lysosomal degradation.  Figure taken from Roopenian & Akilesh, 
2007 4. 
 
Crystal structures of rat FcRn 9, human FcRn 12 and rat FcRn bound to the Fc 
portion of rat IgG at the CH2-CH3 interface 10, 11 were solved.  At the center of 
the Fc/FcRn interface, a hydrophobic core of residues forms, containing Fc I253 
contacting FcRn W133 and Fc P307 contacting β2m I111.  Surrounding the 
hydrophobic core are a network of salt bridges involving acidic FcRn residues 
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(E117, E118, D137) and charged Fc residues (H310, R311, H435, H436) 11.  The 
pH dependence of the FcRn interaction with Fc can be attributed to the titration 
of the contact histidines on Fc.  Neither FcRn nor Fc undergo a major 
conformational change upon binding; but side chains at the interface are 
reoriented 11.   
 
Given the central role of FcRn in regulating serum persistence and transcellular 
permeability of IgG, protein engineers have developed strategies to exploit this 
receptor as a means of enhancing the pharmacokinetic and pharmacodynamic 
properties of biotherapeutics.  Modulation of FcRn binding affinity, through 
selective mutations in the Fc domain of IgG, may potentially provide a way of 
modifying IgG half-life.  
 
Literature-described FcRn binding assays 
There are two widely published formats of FcRn binding assays (Figure 3).  Both 
assays use the surface plasmon resonance (SPR) phenomenon, using BiacoreTM 
instrumentation.   
 
In the first format (Figure 3A), an IgG of interest is directly coupled to a sensor 
surface and FcRn is flowed over the surface 31-33.  Direct coupling of protein to 
the sensor surface allows for random orientation of the IgG on the chip and thus 
a heterogeneous presentation of IgG.  Each IgG is capable of binding two FcRn 
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proteins, on either side of the Fc 34.  With a heterogeneous presentation of IgG 
on the sensor surface, it is possible to mask FcRn binding sites.  Therefore, the 
binding activity of all immobilized molecules on the chip surface may not be 
identical.   Additional drawbacks to this format are low throughput and the high 
cost of sensor chips, as each IgG tested needs to be coupled to a different 
sensor surface. 
 
 
 
 
 
 
 
 
 
Figure 3.  Literature-described FcRn binding assays.  In the first format (A), IgG 
is directly coupled to the sensor, and FcRn is flowed over the surface.  In the 
second format (B) FcRn is directly coupled to the surface, and IgG molecules are 
flowed over the surface.  In this format it is possible that two FcRn molecules 
may bind the same IgG molecule (circled). 
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Y Y YY
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Y
Y
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A
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In the second format (Figure 3B), FcRn is directly coupled to the sensor surface, 
and IgG molecules are flowed over the surface 12, 35.  Direct coupling of FcRn to 
the sensor surface allows for random orientation of the ligand on the chip and a 
heterogeneous presentation of FcRn where sometimes a binding site may be 
masked.  Therefore, the binding activity of all immobilized molecules on the chip 
surface may not be identical.  In these experiments, a relatively high level of 
FcRn is immobilized on the chip, resulting in avidity effects where multiple bond 
interactions can form involving two molecules of FcRn binding to each side of the 
Fc on IgG.  For this reason, a 2:1, or bivalent fit, is used to analyze the data.  The 
output of this fit generates two kinetic affinity values, one for each side of IgG 
binding to FcRn.  This analysis introduces more parameters into the fit, creating 
more degrees of freedom and a better fit, but it is important to note that this fit is 
not necessarily biologically relevant.  This is likely the reason that data in this 
format from different investigators disagree 31, 32, 36, 37.     
 
In many of these assays, IgG molecules flowed over the FcRn immobilized 
surface were not characterized for aggregation.  It is important to ensure the level 
of aggregation in proteins flowed over the surface is low, generally less than 5%, 
in order to ensure uniform binding activity.  When performing BiacoreTM assays, it 
is always better to measure a 1:1 interaction, and this is possible when using the 
second format by coating a lower density of FcRn on the chip to reduce avidity 
effects to the point that they no longer influence the data. 
10 
 
 
A detailed understanding of the FcRn-IgG interaction and a reliable binding 
assay that measures this interaction would have application in the lead 
optimization phase of monoclonal antibody development.  The goal would be to 
obtain a good lead molecule that would have predictable in vivo half-life, as FcRn 
plays an important role in modulating IgG half-life, and IgG half-life in serum may 
correlate with binding affinity to FcRn.  Because the pharmacokinetics of 
therapeutic IgG molecules varies greatly, we set out to systematically examine 
the influence of IgG domains other than the putative FcRn binding site on the Fc 
domain.  We used a sensitive SPR assay that measures a 1:1 interaction 
between IgG and FcRn.  Panels of IgG molecules with several combinations of 
variable and constant domains of heavy and light chains were assembled, and 
binding affinity between these IgG molecules and FcRn were measured using the 
described assay to identify regions of IgG outside the structurally determined 
FcRn binding site on Fc that modulate affinity to FcRn. 
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METHODS 
 
Generation of biotinylated human FcRn- β2m complex 
DNA representing the extracellular domain of FcRn including the signal peptide 
(amino acid residues 1-290; accession no. BC008734) was amplified from cDNA 
(Open Biosystems) using PCR.  The PCR fragments were further extended on 
the 5’ end to add a short linker sequence (GGGSGGG) followed by AviTagTM 
(Avidity, LLC) (GLNDIFEAQKIEWHE) using overlapping PCR.  The resulting 
construct was cloned into a proprietary expression vector.  β2-microglobulin 
(β2m) cDNA (Ultimate ORF clone, Invitrogen) was amplified using PCR (amino 
acids 1-119), and the resulting construct was cloned into a proprietary expression 
vector.  Both FcRn and β2m clones were co-transfected into Chinese hamster 
ovary (CHO) cells, and clones were selected by culturing them in growth medium 
containing 20, 50 or 100 nM MTX and 1 ug/mL G418 to create stable cell lines.  
Clones from each MTX concentration were isolated and cultured in growth 
medium. Supernatants were analyzed for protein expression on 4-12% NuPAGE 
gels (Invitrogen), followed by Western blot using goat polyclonal anti-FcRn 
antibody (Santa Cruz Biotechnology) and mouse monoclonal anti-β2m antibody 
(Santa Cruz Biotechnology).  The best-expressing clonal cell line was selected 
for scale-up.  
Stable CHO lines expressing FcRn were seeded into roller bottles (Cellon) at 
2.7e7 cells/roller bottle.  Four days post seeding the serum containing growth 
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media was removed, the roller bottles were rinsed once with 200 mL of PBS, and 
400 mL/roller bottle of a proprietary serum free media was added.  Seventy two 
hours after changing to serum free media, the conditioned media was removed 
and pooled.   Immediately after harvesting, the pooled conditioned media was 
clarified by filtration and concentrated approximately 20-fold using a 10 kD 
tangential flow filtration cartridge (Millipore Prep Scale Cartridge).  The pH of the 
harvested conditioned medium containing FcRn was adjusted to 5.5-6.0 with 1M 
MES, pH 5.0, and captured on a column containing IgG coupled sepharose6 fast 
flow resin (GE Healthcare).  Following an extensive wash, FcRn- β2m 
heterodimer was eluted in PBS-CMF, pH 7.5.   
Purified FcRn was incubated with biotin ligase and biotin to site-specifically 
attach biotin to lysine residue in the AviTagTM , following manufacturer’s 
instructions (GeneCopoeia).  Biotinylation was confirmed by Western blot 
analysis using streptavidin-HRP (SouthernBiotech) for detection. 
 
Generation of IgG molecules 
Pfizer monoclonal IgG molecules (mAbs) used in this study were discovered 
using both phage display and hybridoma approaches.  PCR site-directed 
mutagenesis was used to introduce mutations into the Fc portion of human IgG1.  
All mAbs used in this study were produced as recombinant proteins using either 
human embryonic kidney (HEK293) cells or CHO cells and purified by Protein A 
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resin (GE Healthcare).  All pure mAbs were determined to be >99% aggregate-
free by analytical size exclusion chromatography.   
 
Replication of published FcRn-IgG binding assay 
To verify the validity of a published binding assay, the affinity to FcRn of 
adalimumab, a commercially available IgG, was determined using the method of 
Suzuki et al. 35, and the data generated were compared to the published data.  
 
SPR FcRn-IgG binding assays 
BiacoreTM T100 or T200 (GE Healthcare) were used to measure steady-state 
binding affinity of the interaction between IgG and FcRn.  Biotinylated human 
FcRn- β2m complex was affinity captured on the surface of a streptavidin (SA) 
chip (GE Healthcare) to a final surface density of 20-70 resonance units (RU).  
IgG analytes were diluted to appropriate experimental concentrations in sample 
buffer (20mM MES, 150nM sodium chloride, 3mM ethylenediaminetetraacetic 
acid, 0.5% P20, pH 6.0) and flowed over the FcRn coated SA chip.  Following the 
association and dissociation phases of the experiment, the SA chip was 
regenerated using 30 s injection of 10 mM HEPES with 150 nM sodium chloride, 
3 mM ethylenediaminetetraacetic acid, 0.05% P20, pH 7.4 (HBS-EP + buffer, GE 
Healthcare) prior to the next cycle.  Unless otherwise mentioned, assays were 
performed in triplicate independently using three different FcRn coated SA chips, 
and the mean steady-state KD value and standard deviation for each IgG 
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molecule were calculated.  IgG molecules described in Table 2 were analyzed in 
only a single experiment due to limited quantities of protein available.  
Appropriate control experiments were carried out to show that mass transport 
was minimal, and the interaction was truly a 1:1 binding event.  The resulting 
sensorgrams were double referenced and fit to steady-state affinity models using 
the Biacore T200 Evaluation Software (version: 1.0, GE Healthcare) or Biacore 
T100 Evaluation Software (version 2.0.1, GE Healthcare).  The validity of the 
data was assessed using calculated chi-square to measure goodness of fit to the 
binding model and Rmax values to verify that all FcRn and IgG molecules are 
actively binding.  
 
50 ug/ml NeutrAvidin, in 10 mM sodium acetate, pH 5.0, was injected over all 
four flow cells on a C1 chip (GE Healthcare) using C1 pre-concentration buffer 
(100 mM glycine, pH 12 with 0.03% TritonX100) to coat all flow cells with 
NeutrAvidin.  Biotinylated human FcRn- β2m complex was affinity captured on 
the NeutrAvidin on flow cells 2-4 to a final surface density of 11.5-40 RU. IgG 
molecules were diluted to appropriate experimental concentrations in sample 
buffer (20mM MES, 150nM sodium chloride, 3mM ethylenediaminetetraacetic 
acid, 0.5% P20, pH 6.0) and flowed over the FcRn coated NeutrAvidin chip.  
Following the association and dissociation phases of the experiment, the chip 
was regenerated using 30 s injection of 10 mM HEPES with 150 nM sodium 
chloride, 3 mM ethylenediaminetetraacetic acid, 0.05% P20, pH 7.4 (HBS-EP + 
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buffer, GE Healthcare) prior to the next cycle.  Assays were performed in 
triplicate independently using three different FcRn coated NeutrAvidin chips and 
the mean steady-state KD value and standard deviation for each IgG molecule 
were calculated.  The resulting sensorgrams were double referenced and fit to 
steady-state affinity models using the Biacore T200 Evaluation Software (version: 
1.0, GE Healthcare).  The validity of the data was assessed using calculated chi-
square to measure goodness of fit to the binding model and Rmax values to 
verify that all FcRn and IgG molecules are actively binding. 
 
Thermal stability of IgG at pH 6.0 and 7.2 
Solutions of each IgG molecule (0.1 mg per mL in buffer) were heated at 1°C per 
min from 20 to 95°C in the presence of a dye, Sypro Orange. Sypro Orange 
binds to partially folded protein structures and in doing so its fluorescence 
intensity is enhanced. Mathematically fitting the plot of fluorescence intensity 
against temperature, the individual unfolding transitions can be extracted.  Each 
sample was run in quadruplicate at both pH 7.2 and 6.0.  
 
Isothermal titration calorimetry affinity measurements 
ITC experiments were carried out using a VP-ITC instrument (GE Healthcare), 
and data were analyzed using Origin 7 (OriginLab). All experiments were 
performed with FcRn in the sample cell and IgG in the syringe.  Both FcRn and 
IgG were extensively dialyzed in 50 mM sodium phosphate, 150 mM sodium 
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chloride, pH 6.0, and the same buffer was used in the reference cell.  
Concentrations of FcRn and IgG were adjusted to 0.014 mM or 0.028 mM (FcRn) 
and 0.11 mM (IgG) using the buffer mentioned above and degassed prior to 
adding to reactant cell and titrating syringe.  All runs were performed at 20°C, 
and each run comprised a series of twenty-two 13.3 µL injections of IgG with 
syringe stir speed of 470 rpm. The injections were spaced 300 s apart to allow 
time to reach equilibrium prior to the next injection.  Data were analyzed using 
Origin 7.0 (Origin Lab) and fit to the one site binding model to calculate 
stoichiometry and binding affinity. 
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RESULTS 
 
Development of an SPR assay to measure FcRn-IgG binding in vitro 
To verify the validity of a published binding assay, the affinity to FcRn of 
adalimumab, a commercially available IgG, was determined using the method of 
Suzuki et al. 35, and the data generated were compared to the published data. In 
the publication, the authors note that with increasing concentrations of IgG there 
is non-specific background binding to the sensor surface, making analysis above 
the calculated KD value inaccurate.  Most of the highest reported concentrations 
injected are at or just above the KD value, not fitting with good practice. When 
performing kinetic experiments on the BiacoreTM, it is good practice to inject at 
least five replicate concentrations of 0.1-10 times KD, and the highest 
concentration should plateau to reach steady-state 38, 39.  In replicating this 
assay, buffer conditions were adjusted to include two times the amount of sodium 
chloride (300mM) in order to eliminate non-specific background binding when 
injecting higher concentrations of IgG.  Injecting the same concentration range of 
adalimumab (0, 42, 84, 168, 335, 670 nM) resulted in an affinity value to FcRn of 
923 nM. The reported affinity value for adalimumab was 670 nM.  These values 
are comparable, as common practice dictates that affinity data within a two-fold 
range is considered similar. Injecting an additional concentration of adalimumab 
at 1340 nM in the optimized buffer resulted in an affinity value of 4531 nM, an 
almost 5-fold lower affinity.   
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To overcome the limitations of this particular FcRn-IgG binding assay, a more 
robust assay was desired where affinity could be measured over a wide range of 
affinity values and increasing concentrations of IgG would not alter reported 
affinity values.  All literature described methods measure both association and 
dissociation of the IgG-FcRn complex at pH 6.0.  Physiologically, association 
occurs at endosomal pH (<pH 6.5), but dissociation occurs at serum pH (around 
pH 7.4).  In the assay, measuring association at pH 6.0 and dissociation at pH 
7.4 does not allow for an accurate calculation of affinity since dissociation values 
are outside of instrument limitations (above 10-1 s-1) because of the rapid 
dissociation at pH 7.4.  Additionally, for a good understanding of the interaction 
between IgG and FcRn, we believe it is highly desirable to preserve the natural 
state of an IgG molecule, including its quaternary structure and inherent flexibility 
in solution during binding experiments, as this is what occurs in vivo.  For this 
reason we believe it is important to keep IgG molecules in solution and coat 
FcRn on the sensor surface. 
 
Design of a new format of SPR assay was implemented to measure the IgG-
FcRn interaction.  A novel assay was required as the existing formats either 
limited the flexibility of IgG by immobilizing it directly to the sensor surface or 
measured avidity from FcRn that is randomly immobilized, in high density, to the 
sensor surface.  This alternative SPR assay was designed to allow for a 1:1 
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interaction between FcRn and IgG. As depicted in Figure 4, biotinylated FcRn 
(through an AviTagTM on C-terminus) was coupled to a streptavidin sensor chip 
allowing homogeneous orientation of FcRn. To avoid avidity contributions that 
would complicate the data analysis, we tested IgG binding to FcRn coupled to 
the sensor chip at low density.  A set of sensorgrams representing the binding of 
IgG (as a series of concentrations) to FcRn at pH 6.0 and dissociating at pH 7.4 
is shown in Figure 5A. As shown, binding using this assay format is 
characterized by fast association and dissociation that precluded use of available 
kinetic models to reliably analyze the data and obtain kinetic parameters. 
Instead, as rapid binding equilibrium was achieved at every concentration of IgG 
tested, we resorted to steady-state analysis of the data. A representative data set 
demonstrating the binding response as a function of the IgG concentration and 
the corresponding curve fit is shown in Figure 5B and was used to calculate 
steady-state KD. Coating the sensor surface with FcRn concentrations above 70 
resonance units (RU) resulted in higher affinity values, poor fit of steady-state KD 
and non-linear Scatchard plots, indicating that avidity contributes to the affinity 
values with higher concentrations of FcRn on the surface.  Thus, all binding 
studies were carried out in the range of 20 -70 RU of FcRn on the sensor 
surface. 
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Figure 4.  Format of new FcRn-IgG binding SPR assay.  Low density biotinylated 
FcRn (through an AviTagTM on C-terminus) was coupled to a streptavidin sensor 
chip surface allowing homogeneous orientation of FcRn, and IgG molecules were 
flowed over the surface. 
  
SA chip 
Y Y Y Y 
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Figure 5.  IgG binding to FcRn in the newly developed SPR assay.  (A) 
Sensorgram representing the binding of IgG molecules (as a series of 
concentrations) to FcRn at pH 6.0 and dissociating at pH 7.4.  The variable 
region from trastuzumab was cloned onto wild-type heavy chain subclass IgG2 
and was injected over FcRn at 0, 31.3, 62.5, 125, 250, 500, 1000, or 2000 nM.  
Steady-state affinity KD values at equilibrium were fit using Biacore software; the 
affinity of trastuzumab to FcRn in this experiment was 513.4 nM. (B) A 
representative data set demonstrating the binding response as a function of the 
IgG concentration used to calculate steady-state KD. 
A 
B 
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 To examine the pH-dependent binding of IgG to FcRn in this assay format, 
binding of multiple IgG molecules to FcRn was observed with binding present at 
pH 6.0 and absent at pH 7.4.  A representative IgG, PFE-4 is depicted in Figure 
6. Thermal stability studies were carried out on a set of nine different IgG 
molecules at pH 7.2 and 6.0 to confirm that IgG molecules are stable at both pH 
values (Figure 7). 
 
 
 
 
 
 
 
Figure 6. pH-dependent binding of IgG to FcRn.  Binding of >1 uM concentrations 
of PFE-4 IgG to FcRn occurs at pH 6.0 (red) but not at pH 7.4 (green). 
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Figure 7.  Thermal stability of IgG molecules is similar at pH 6.0 and 7.2.  Figure 
(A) is a bar graph histogram revealing the thermal transitions measured on nine 
IgG molecules at pH 7.2: red (CH2), green (Fab) and blue (CH3).  The 
superimposed symbols are the thermo-melting temperatures (Tm) of the IgG 
molecules tested at pH 6.0, and fall within Tm values of the same IgG molecules 
tested at pH 7.2.  Figure (B) plots Tm at pH 7.2 against pH 6.0.  The line is the 
identity line, if the stabilities were exactly identical at the two pH values. Fit of the 
experimental data to a straight line generates an R2 value of 0.98 indicating that 
the thermal stability of these IgG molecules is similar at both pH values.  
 
Previously identified mutations in the Fc region of IgG shown to modulate binding 
to FcRn were tested in the assay.  Mutations introduced into the Fc region of IgG 
(M428L/N434S) have been demonstrated to enhance the affinity of IgG to FcRn 
CH2 CH3
Fab
R2 = 0.98
A B 
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40.  When these mutations were introduced into two different IgG molecules of 
interest, PFE-8 and PFE-10, binding affinity of mutated IgG was enhanced 4.3 
and 12.3-fold compared to wild-type IgG, respectively (Figure 8).  Mutation of key 
contact histidine residues in the Fc region of IgG (H310A and H435A) have been 
demonstrated to abolish the interaction of IgG with FcRn 41-44.  When these 
mutations were introduced, either in combination or one at a time, into five IgG 
molecules of interest, binding of mutated IgG to FcRn was completely abolished 
(Figure 9).  
 
Figure 8.  Known mutations in the Fc region of IgG enhance binding of IgG to 
FcRn.  Representative sensorgrams from injection of increasing concentrations 
of an IgG molecule, PFE-8, with both wild-type (red) and mutated 40 (green) Fc.  
Concentrations injected were 0, 23.4, 46.9, 93.8, 187, 5, 375, 750, 1500, 3000 
nM.  In this experiment, the presence of Fc mutations increased steady-state 
binding affinity of this IgG by 4.3-fold, as indicated by a decrease in the KD from 
245.8 nM (wild-type) to 56.8 nM (M428L/N434S). 
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Figure 9.  Mutation of key contact histidine residues in the Fc region of IgG 
abrogates binding of IgG to FcRn.  Representative sensorgram from injection of 
3000 nM of an IgG molecule, bevacizumab, with H435A mutation in one of the 
key histidine contact residues of the Fc region.  Binding of IgG to FcRn is 
completely abolished with this mutation.   
 
In addition, we observed that the binding affinity of antigen-complexed IgG to 
FcRn was 3 to 96-fold lower for three different IgG molecules, against the same 
target antigen, compared to that of uncomplexed IgG to FcRn (Table 1). This 
observation suggested that IgG flexibility in the CDRs influences the interaction 
of IgG with FcRn.   
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Table 1.  Binding IgG molecules to target antigen alters the binding affinity of IgG 
to FcRn.  Three IgG molecules with similar affinity for the same target antigen 
were tested alone or pre-complexed to antigen in the FcRn binding assay.  Each 
experiment was completed in triplicate and mean steady-state KD and standard 
deviation were calculated. 
IgG Experimental format Mean steady-state binding KD (nM) 
PFE-4 IgG over FcRn   348.8 ± 20.9 
PFE-4 IgG-antigen precomplex 
over FcRn 
1060.0 ± 24.0 
PFE-11 IgG over FcRn     10.7 ± 1.15 
PFE-11 IgG-antigen precomplex 
over FcRn 
1024.6 ± 64.2 
PFE-12 IgG over FcRn     68.6 ± 7.75 
PFE-12 IgG-antigen precomplex 
over FcRn 
1062.5 ± 21.9 
 
To further validate the assay format, an orthogonal technique, ITC, was used to 
calculate the binding affinity between three IgG molecules and FcRn.  As 
presented in Table 2, all three IgG molecules showed distinctly divergent binding 
affinities to FcRn. However, any given IgG molecule exhibited similar binding 
affinity, whether measured by SPR or ITC, as indicated by the R2 correlation 
value of  0.99. In addition, an excellent fit of ITC data to a model of a single class 
of identical binding sites (Figure 10) suggested binding stoichiometry of two 
symmetric identical sites for FcRn on IgG, well in agreement with previous 
observations. 45 The correlation between binding affinities measured using two 
independent techniques supported the validity of the SPR assay format, which 
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was then used to explore the IgG domains influencing the binding affinity of IgG 
to FcRn and their implications in vivo. 
 
Table 2.  Comparison of binding affinity data measured using SPR and ITC.  
Steady-state KD affinity values from the SPR binding assay, ITC affinity values, 
and IgG: FcRn stoichiometry values from ITC experiments are listed for three IgG 
molecules 
IgG Mean steady-
state KD (nM) 
ITC affinity (nM) Stoichiometry 
(IgG:FcRn) 
PFE-1 186.4 ± 1.57 144 ± 8.33 0.634 ± 0.00715 
PFE-2 848.0 ± 89.8 1029 ± 79.4 0.511 ± 0.0134 
PFE-4 348.8 ±20.9 285 ± 2.04 0.507 ± 0.00531 
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Figure 10.  IgG binding to FcRn in the ITC binding experiment.  Trace and model 
fit of an IgG molecule, PFE-4, injected into FcRn. 
 
Identification of IgG regions that affect affinity to FcRn 
To identify domains of IgG that affect affinity to FcRn, other than those in the Fc 
region, panels of IgG molecules with distinct characteristics were tested for FcRn 
binding using the assay described in the preceding section.  The panels included: 
(panel 1) IgG molecules representing subclasses IgG1, IgG2, and IgG4 bearing 
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identical variable domains and light chain subclass to assess binding 
contributions of heavy chain isotype; (panel 2) IgG molecules with either kappa 
or lambda light chains and identical heavy chains to assess binding contributions 
of light chain isotype; (panel 3) IgG molecules with different variable domain 
frameworks and identical heavy and (or) light constant domains to assess 
binding contributions of framework regions; (panel 4) IgG molecules with 
specificity to different target antigens and having different CDR sequences, but 
identical variable framework sequences and constant domains to assess binding 
contributions of CDRs; and (panel 5) IgG molecules with some mutations in 
CDRs only to assess binding contributions of small changes in CDRs. 
 
In order to determine the contribution of heavy chain subclass to the affinity of 
IgG to FcRn, IgG molecules containing variable domains derived from two 
commercial monoclonal antibodies (mAbs), bevacizumab and trastuzumab, and 
one Pfizer proprietary mAb, PFE-3, were generated on subclasses IgG1, IgG2 
and IgG4. All of these IgG molecules contain a kappa light chain. Three key 
FcRn contact residues on IgG (I253, H310, H435) are conserved in these three 
heavy chain subclasses, and when mutated were shown to ablate affinity 
between IgG and FcRn 46.  Binding affinity of IgG molecules in this panel to FcRn 
was measured and reported in Figure 11.  Interestingly, the affinities of all three 
subclasses of bevacizumab to FcRn ranged from 279.1 to 308.2 nM, and were 
not statistically different from one another, indicating that changes in the heavy 
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chain constant domains that are away from the conserved putative FcRn binding 
site do not alter the interaction of IgG to FcRn.  Similar observations have been 
made between IgG1 and IgG2 subclasses of trastuzumab and PFE-3. However, 
statistical analysis by both paired t-test and ANOVA revealed that the IgG4 
subclass has significant marginal differences in binding affinity compared to the 
IgG1 or IgG2 subclasses for trastuzumab and PFE-3.  Surprisingly, a difference 
in the binding affinity up to 2.5-fold was observed between the antibodies of 
similar subclass (e.g., IgG1 versions of bevacizumab, trastuzumab and PFE-3) 
suggesting an influence of changes in variable domains on the affinity of IgG to 
FcRn.  This is in agreement with recent observations that the Fab domain of 
monoclonal IgG molecules affects IgG interaction with FcRn 35, 47, thus, 
prompting us to further investigate the role of various structural elements of Fab 
domains on the IgG interaction with FcRn.  
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Figure 11.  Heavy chain subclass does not alter the interaction of IgG to FcRn.  
Each set of IgG molecules with differing heavy chain subclasses were tested for 
affinity to human FcRn in the SPR assay a minimum of three times on three 
different surfaces in three separate experiments.  Mean steady-state KD values 
for each IgG molecule were plotted with error bars indicating standard deviations.  
Each set of IgG molecules, containing the same variable sequence and light 
chain subclass, is colored differently.  Steady-state KD values appear above each 
data point. 
 
The Fab domain constitutes variable and constant domains of heavy and light 
chains. Panel 2 represents a set of IgG molecules that differ in the light chain 
subclass and contain identical heavy chain subclass (IgG1). As shown in Figure 
13, a wide range of FcRn binding affinity values were observed for all of the 
mAbs within each kappa and lambda group, kappa ranging from 10.7 to 811 nM 
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and lambda ranging from 12.6 to 848 nM. In addition, two versions of an antibody 
with identical target binding affinities but differing constant light chain domains 
(one kappa and the other lambda) bound to FcRn with similar affinity (data not 
shown). This observation, together with those described in Figure 12, 
strengthened the hypothesis that variable domains, which contain domains from 
both heavy and light chains, could modulate binding affinity to FcRn. Variable 
domains of both heavy and light chains can be further divided into frameworks 
and CDRs that are anchored by frameworks. In order to determine the 
contribution of variable domain frameworks to the affinity of IgG to FcRn, panel 3 
mAbs with different heavy and light chain variable domain framework families 
and identical corresponding heavy and light chain subclasses were compiled and 
tested for binding to FcRn.  As shown in Figure 13A, IgG molecules bearing 
similar VH frameworks bound FcRn with differing affinity; while the VH1 family 
showed affinity values of 108.8 and 340.1 nM, the VH3 family showed affinity 
values of 45.9 and 314.1 nM.  Comparable observations have been made for 
antibodies bearing similar variable kappa (VK) or variable lambda (VL) 
frameworks (Figure 13B), suggesting that variable domain frameworks may not 
contribute to the interaction of IgG with FcRn.  Because no correlation between 
affinity of IgG to FcRn and the variable domain frameworks was observed, we 
further hypothesized that CDRs might play a role in modulating affinity to FcRn. 
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Figure 12.  Light chain subclass does not alter the interaction of IgG to FcRn.  A 
panel of IgG molecules containing kappa or lambda light chains all paired with 
the same heavy chain subclass (IgG1) was compiled and tested for affinity to 
FcRn in the SPR assay a minimum of two times in duplicate on two different 
surfaces in two separate experiments.  The mean steady-state KD values for 
each IgG molecule were plotted with error bars representing standard deviations.  
Kappa and lambda containing IgG molecules are colored differently.  
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Figure 13.  Variable domain framework family does not alter the interaction of 
IgG to FcRn.  A panel of IgG molecules containing different variable domain 
framework families all paired with identical heavy and light chain subclasses was 
compiled and tested for affinity to FcRn in the SPR assay a minimum of two 
times in duplicate on two different surfaces in two separate experiments.  Mean 
steady-state KD values for each IgG molecule was plotted with error bars 
representing standard deviations.  Different variable domain framework 
containing IgG molecules reduce number of adjectives for noun, is this 
framework-containing? are colored differently.  Steady-state KD values appear 
above each data point.  A.  Heavy chain variable domain families VH3 and VH1.  
B.  Light chain variable domain families VK2 and VK1, and VL3 and VL1. 
A 
B 
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To further test the influence of CDRs on the IgG affinity to FcRn, six IgG 
molecules (panel 4) containing identical constant domains and framework 
residues, but different CDRs allowing for binding to different targets were 
assessed for binding to FcRn.  The six IgG molecules exhibited affinities to FcRn 
in the range of 49.3-1318 nM, indicating that CDR sequences can alter the 
affinity of IgG to FcRn (Figure 14).  To validate this observation, a different set of 
twenty-nine IgG molecules with a small number of mutations in CDRs only was 
complied and are described in Table 3.  IgG molecules in this set were derived 
from the same parent antibody but had higher binding affinity to antigen.  In any 
given IgG within the set, one to five mutations in CDRs could be found.  The IgG 
molecules exhibited affinities to FcRn in the range of 3.2-253.1 nM, indicating 
that even marginal changes in CDR residues of an IgG molecule can 
dramatically alter the binding affinity of IgG to FcRn (Table 3).  Intrigued by this 
observation, we queried if the Fab domain alone could bind to FcRn in the 
absence of binding at the putative site on the Fc domain.  To address this 
question, IgG molecules that exhibited higher affinities in the range of 15.4-104.3 
nM to FcRn were mutated at the two key histidine contact residues (H310A, 
H435A).  These mutations have been shown to ablate the interaction between 
IgG and FcRn 48, 49.  A representative sensorgram resulting from binding of PFE-
14 to FcRn is presented in Figure 15.  As shown, no interaction was measured 
between IgG mutant and FcRn even at IgG mutant concentration as high as 
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667 nM (a concentration value just above 6-fold the steady-state affinity value of 
the wild-type IgG).  Based on this observation, we concluded that the interaction 
between the Fc that constitutes the putative binding site and FcRn is absolutely 
necessary and contributes the majority of binding energy, while minor 
contributions from CDRs can further strengthen the interaction. It is possible that 
residues in CDRs could directly contact FcRn following the first interaction at the 
putative binding site by indirectly affecting the flexibility of Fab arms. 
 
 
Figure 14.  CDR sequences can alter the binding affinity of IgG to FcRn.  Mean 
steady-state KD values for each IgG molecule was plotted with error bars 
representing standard deviations.  Each IgG molecule contains identical constant 
domains and framework residues, but different CDR sequences.  Steady-state KD 
values appear above each data point. 
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Table 3.  Small variations in CDRs alter affinity of IgG to FcRn.  Each IgG 
molecule differs only by 1-5 mutations in CDR sequences and was tested for 
affinity to FcRn in the SPR assay. 
IgG SS KD to 
FcRn (nM) 
Mutation Notes H-CDR 
mutations 
L-CDR 
mutations 
PFE-A 253.1 Parental 0 0 
PFE-B 204.2 CDR-L3 0 1 
PFE-C 202.3 CDR-L3 0 1 
PFE-D 146.0 CDR-H1 1 0 
PFE-E 144.1 CDR-H1, L1 1 1 
PFE-F 142.7 CDR-H1, H2, L3 2 1 
PFE-G 130.9 CDR-H1, H2, L1 2 1 
PFE-H 103.1 CDR-H1, L3 1 1 
PFE-I 87.6 CDR-H1 1 0 
PFE-J 72.1 CDR-H1, H2, L1 2 1 
PFE-K 69.0 CDR-H1, H2, L3 2 1 
PFE-L 64.7 CDR-H2, L3 1 1 
PFE-M 61.5 CDR-L3 0 3 
PFE-N 60.1 CDR-L3 0 1 
PFE-O 46.7 CDR-H1, L3 1 1 
PFE-P 44.5 CDR-H2, L3 1 1 
PFE-Q 42.8 CDR-H2, L3 1 1 
PFE-R 41.2 CDR-L3 0 1 
PFE-S 36.9 CDR-H2, L3 1 4 
PFE-T 33.0 CDR-L3 0 3 
PFE-U 27.3 CDR-H1, H2, L3 2 3 
PFE-V 24.4 CDR-L3 0 4 
PFE-W 18.6 CDR-H1, L3 1 1 
PFE-X 18.1 CDR-L3 0 4 
PFE-Y 14.5 CDR-H1, L3 1 1 
PFE-Z 13.2 CDR-H1, H2, L3 2 1 
PFE-AA 4.5 CDR-H1, L3 1 1 
PFE-AB 3.4 CDR-H1, L3 1 1 
PFE-AC 3.2 CDR-H1, H2, L3 2 1 
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Figure 15.  No binding is observed between the Fab domain and FcRn.  Variable 
domains from PFE-14 were cloned onto IgG1 subclass with mutations in the two 
key histidine contact residues to ablate the interaction between the Fc regions of 
IgG and FcRn.  No interaction was measured after injecting these IgG molecules 
at maximum concentrations just over six times the steady-state affinity of the 
wild-type IgG1 molecule. 
 
Correlation between isoelectric point of various domains of IgG and affinity to 
FcRn 
Both the observations described in the preceding paragraphs and recent 
observations by Igawa et al. 50 demonstrating an effect of framework region pIs 
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on antibody in vivo half-life encouraged us to hypothesize that charges in CDR 
domains may directly or indirectly influence IgG affinity to FcRn. To test the 
hypothesis, pI values were theoretically calculated for various domains of IgG 
molecules from panel 4, which differ in CDRs only (Table 4). The mean steady-
state KD of the interaction between FcRn and each IgG molecule tested, as well 
as pI values for variable regions and each CDR of IgG were also calculated 
(Table 4). As shown in Figure 16, variable domain pI correlated very well with 
IgG affinity to FcRn, indicating that charge modulation in the CDRs of variable 
domains can affect the FcRn binding affinity.  Further analysis of IgG binding 
affinity in correlation with individual CDR pI revealed good correlation with 
changes in CDR-L3, H3 and L1. In contrast, no correlation was observed when 
the pI of the entire IgG was calculated, indicating that local pI changes affect IgG 
binding to FcRn.  Moreover, no correlation was observed with CDR-L2, H1 or H2. 
To further validate this observation, a subset of the IgG molecules with few 
mutations in CDR-L3 only was analyzed.  An increase in the pI of CDR-L3 
strongly correlated with an increase in binding affinity of IgG to FcRn (Table 5 
and Figure 17).   
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Table 4.  CDR sequences can alter affinity of IgG to FcRn.  Each IgG molecule 
contains identical constant domains and framework residues but different CDR 
sequences.  Mean steady-state KD values and standard deviations were 
calculated from three separate experiments.  Isoelectric points of variable regions 
and individual CDRs of IgG molecules were theoretically calculated using 
ExPASy (Swiss Institute of Bioinfomatics). 
IgG Mean KD 
(nM) 
pI 
Varia
ble 
pI 
CDR-
H1 
pI 
CDR-
H2 
pI 
CDR-
H3 
pI 
CDR-
L1 
pI-
CDR-
L2 
pI 
CDR
-L3 
PFE-5 49.3 ± 
6.9 
9.41 5.52 6.75 5.83 11.10 9.75 8.59 
PFE-6 416 ± 
20.0 
9.16 5.52 9.70 4.21 9.76 5.24 5.52 
PFE-7 437 ± 
101 
7.06 6.74 6.04 3.43 6.76 11.00 6.74 
PFE-8 811 ± 
113 
5.55 5.52 4.79 3.42 5.84 8.75 3.80 
PFE-9 1033 ± 
126 
6.85 5.52 5.55 3.80 6.75 6.00 3.67 
PFE-10 1318 ± 
206 
5.22 5.52 3.96 3.56 5.84 6.09 4.13 
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Figure 16.  Correlation of various pI values with affinity to FcRn.  pI values for 
variable regions (R2 = 0.7261), CDR-L3 (R2 = 0.7767), H3 (R2 = 0.4877) and L1 
(R2 = 0.6776) all correlate with affinity to FcRn.  No correlation was observed with 
pI of the entire IgG, CDR-L2, H1 or H2. 
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Table 5.  Steady-state affinity and pI value of IgG with small changes in CDR-L3.  
Three IgG molecules that differ by one residue in CDR-L3 were tested in the 
SPR assay.  Mean steady-state KD values and standard deviations were 
calculated from three separate experiments.  Isoelectric points of the CDR-L3 
were theoretically calculated using ExPASy (Swiss Institute of Bioinfomatics). 
IgG Mean SS KD (nM) pI CDR-L3 
PFE-11 10.73 ± 1.15 11.00 
PFE-12 68.60 ± 7.75 7.95 
PFE-13 119.46 ± 9.10 6.00 
 
 
Figure 17.  Higher pI values of CDR-L3 correlate with higher affinity to FcRn.  
Plotting the steady-state KD vs. pI of CDR-L3 demonstrated a strong positive 
correlation between pI value and affinity to FcRn (R2 = 0.9921). 
 
Based on these observations and our understanding of the contribution of CDRs 
to modifying affinity to FcRn, a structural model was generated to examine 
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whether CDR-L3 in the Fab arm of an IgG would come directly in contact with 
FcRn (Figure 18).  After examining the model, we hypothesized that flexibility in 
the hinge of IgG may allow for Fab arm contact with either FcRn directly or the 
plasma membrane of cells expressing FcRn following binding to FcRn.  In the 
SPR assay, the streptavidin that the biotinylated FcRn is coupled to has been 
attached to a carboxymethyl dextran matrix.  This matrix is made up of polymers 
of glucose and is negatively charged and extremely flexible, allowing for free 
movement of attached FcRn and thus may mimic the negatively charged plasma 
membrane.  In order to examine the effect of the carboxymethyl dextran matrix in 
the assay, NeutrAvidin, a neutral charged version of streptavidin, was coupled to 
a C1 sensor, a flat carboxymethylated surface with no dextran matrix.  
Biotinylated FcRn was coupled to the sensor surface and binding experiments of 
three IgG molecules were carried out to examine the matrix effect on FcRn 
binding.  As reported in Table 6, presence of the matrix affects the binding affinity 
of some IgG molecules to FcRn, but not others.  We additionally observe higher 
standard deviations for the IgG molecules on the SA sensor, due to variations of 
the interaction of IgG in solution with the charged matrix, compared with lower 
standard deviations for the IgG molecules on the C1 sensor (Table 6),
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Figure 18.  Model of IgG binding to FcRn.  FcRn is a heterodimer consisting of a 
MHC-class-I-like heavy chain (shown in red) and a β2m light chain (shown in 
blue).  The figure displayed is modeled on the crystal structure of rat FcRn 
binding to rat IgG2a Fc (PDB ID: 1FRT11) superimposed with modeled IgG1 
based on the crystal structure of IgG1 (PDB ID: 1HZH). 
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Table 6.  Presence of the carboxymethyl dextran matrix alters steady-state KD of 
some IgG molecules to FcRn, but not others.  The FcRn SPR binding assay was 
carried out on SA chips with a carboxymethyl dextran matrix and on NeutrAvidin 
coated on a C1 chip with no matrix for three IgG molecules on at least three 
experiments on a minimum of two different surfaces.  Mean steady-state KD is 
statistically similar for PFE-1 and PFE-4 but differs significantly for PFE-2 by 
paired t-test. 
IgG Sensor chip used Mean steady-state KD (nM) 
PFE-1 C1 coated with NeutrAvidin   377.5 ± 7.8 
PFE-1 SA on carboxymethyl dextran matrix   454.0 ± 103.9 
PFE-2 C1 coated with NeutrAvidin   661.4 ± 64.7 
PFE-2 SA on carboxymethyl dextran matrix 1264.6 ± 267.8 
PFE-4 C1 coated with NeutrAvidin   756.9 ± 42.1 
PFE-4 SA on carboxymethyl dextran matrix   764.8 ± 173.6 
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DISCUSSION 
 
A large body of literature exists demonstrating the role of FcRn in extending the 
half-life of therapeutic antibodies by rescuing them from lysosomal degradation.  
Despite all the therapeutic antibodies being of the IgG subclass, they differ 
substantially in their in vivo half-lives, which depend on several factors such as 
FcRn affinity. In addition to FcRn binding affinity, a major factor that influences 
the half-life of IgG molecules is target-mediated disposition.  However, studies 
have shown that even in the absence of target-mediated disposition, in vivo half-
lives have differed significantly, indicating that other factors might be playing a 
role.  For example, specific off-target binding of a humanized anti-fibroblast 
growth factor receptor 4 (FGFR4) IgG to mouse complement component 3 
exhibited rapid clearance in mice 51.  Non-specific binding of IgG may also result 
in poor serum pharmacokinetics, as was seen with palivizumab, an anti-RSV 
mAb 52.  Several studies have demonstrated that in vivo half-life can be 
manipulated by modulating the binding affinity between IgG and FcRn by 
engineering the Fc region of IgG and introducing mutations that enhance FcRn 
binding at endosomal pH, where IgG is exposed to FcRn, but not at neutral pH, 
allowing for IgG to dissociate from FcRn after fusion with plasma membrane. 33, 
40, 53, 54  In the present study we sought to understand the role of different IgG 
domains that are distal from the putative binding site in modulating the affinity 
between IgG and FcRn.  
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Therapeutic IgG antibodies are of different subclasses and are multi-domain 
proteins, each domain serving a distinct function.  Studies measuring human 
maternal-fetal transport of IgG have shown differences in transport for the four 
heavy chain subclasses, in the order of IgG1 > IgG4 > IgG3 > IgG2. 55  Based on 
this study, it has been widely assumed that FcRn recycling is most effective with 
the IgG1 heavy chain subclass.  In contrast to this widely accepted hypothesis, 
we have demonstrated that the affinity of IgG with identical variable domains to 
FcRn is identical for IgG1 and IgG2 subclasses and similar for IgG4 (Table 3).  It 
has been demonstrated that the IgG4 hinge has enhanced flexibility compared to  
that of IgG1; 56 therefore, it is possible that in the case of IgG4, additional hinge 
flexibility alters its interaction slightly to FcRn and may account for the small 
binding affinity change we observed.  While IgG subclass showed no significant 
effect on FcRn binding affinity, surprisingly, the Fab domain significantly 
impacted binding affinity, as exemplified by the FcRn binding of three different 
antibodies of identical subclass (Figure 4).  Such behavior has recently been 
observed by other groups, substantiating our observations 47.  Encouraged by 
this observation, we sought to systematically dissect the contributions of variable 
domain in modulating the affinity between FcRn and IgG.   
 
The variable domain is comprised of frameworks that form the core and CDRs or 
paratopes that confer specific binding to the cognate antigen.  This study 
indicates that the framework domains comprising both heavy and light chains did 
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not affect FcRn affinity to IgG as wide ranges of affinity values were measured 
for IgG molecules containing similar framework domains. The next logical step 
was to evaluate the contribution of CDR domains to FcRn affinity.  The binding 
affinity of IgG molecules to FcRn that differed by only a few amino acid residues 
in CDRs revealed that small changes in CDRs, as minute as one amino acid 
residue change, could alter affinity to FcRn by 10 to 80-fold.  These observations 
are intriguing as CDR domains are located far from the putative FcRn binding 
site on the Fc.  This led us to question whether CDRs could directly contact FcRn 
or the nearby plasma membrane, influence flexibility of the Fab arm, and/or 
influence the tertiary and/or quaternary structure of IgG, and thus modulate 
affinity of IgG to FcRn.  It is generally surmised that individual IgG molecules are 
highly flexible, allowing crosstalk between Fab and Fc domains.  Inherent 
flexibility of IgG increases the likelihood of its contact with the cognate antigen.  
The Fab arm can rotate as much as 158° and the Fab-Fc angles ranged from 63-
172° as revealed by electron tomography studies 57, 58 and examination of 
existing crystal structures.  Such flexibility might increase the likelihood of 
variable domains initiating contact with FcRn, especially the β2m subunit 
following FcRn binding at its primary binding site on the Fc domain.  Figure 19 
illustrates a model of human FcRn in complex with human IgG, constructed 
based on the crystal structure of rat Fc-FcRn and demonstrates the possibility of 
direct contact between the Fab arm and FcRn.  However, under the SPR 
conditions we tested, a direct interaction between FcRn and the Fab domains 
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has not been observed in the absence of a primary interaction at the Fc domain 
(Figure 15). We reasoned that this interaction may not be as strong and/or 
specific enough that it could be detected in our SPR assay.  Nevertheless, this 
weak interaction could securely position the FcRn molecule and strengthen the 
primary interaction at the putative site.   
 
The other likely biological surface IgG may contact following its binding to FcRn 
is the plasma membrane of cells expressing FcRn. This has been suggested as 
a possibility by Burmeister 9 based on the rat Fc-FcRn crystal structure and 
modeling. Further evaluation of the structural model suggests that the Fab 
domain would likely come in contact with the plasma membrane. Based on these 
assumptions, we hypothesized that modifying charges in CDRs could modulate 
this secondary contact. Upon measuring the binding affinities of a panel of mAbs 
whose variable domain pI values ranged from 5-9 as a result of 1-5 amino acid 
substitutions in CDRs, we found that the higher the pI, the tighter the binding.  
Further dissection of the variable domain pI showed that higher pIs of CDR 
domains H3, L1 and L3 correlated with increased affinity to FcRn; among them 
L3 showed the strongest correlation.  We also examined the influence of the 
negatively charged carboxymethyl dextran matrix, likened to mimicking the 
negatively charged plasma membrane, and saw that the presence of the matrix 
alters the interaction of some IgG molecules to FcRn but not others.  Depending 
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on local charges on the IgG molecule, it is possible that the matrix may attract or 
repel the IgG and thus alter its affinity to FcRn.   
 
While several factors can influence the in vivo half-life of an IgG molecule, FcRn 
binding to IgG is one of the key factors.  Encouraged by other published findings, 
such as those of Igawa et al. 50 demonstrating that changes in the variable 
domain pI as a result of substitutions in the framework domains influenced IgG in 
vivo half-life and based on our in vitro observations, our working hypothesis is 
that IgG molecules with higher affinity to FcRn as a result of contributions from 
the Fab arm may not rapidly dissociate from FcRn at the cell surface during the 
kiss-and-run fusion and are re-internalized with FcRn, possibly leading to 
degradation via lysosomal pathways.  This would have far-reaching implications 
in the optimization efforts of IgG therapeutics with respect to in vivo half-life.  
However, this hypothesis needs further investigation with correlations between in 
vitro binding of IgG molecules to FcRn and in vivo half-lives of the same IgG 
molecules. 
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